Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)
- 1 July 2001
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 11 (s1) , 73-76
- https://doi.org/10.1046/j.1525-1438.2001.11(suppl.1)sup1073.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]JNCI Journal of the National Cancer Institute, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trialsBritish Journal of Cancer, 1998
- ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancerThe Lancet, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991